Should You Consider Investing in Halozyme Therapeutics (HALO)?

Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. Small-cap stocks overall posted rather disappointing returns in the second quarter of 2022. In what has become a common theme, the Russell 2000® Growth Index (down 19.26%) significantly lagged its Russell 2000® Value Index (down 15.28%) counterpart and has now trailed in seven consecutive quarters Go over the fund’s top 5 positions to have a glimpse of its finest picks for 2022.

In its Q2 2022 investor letter, Carillon Eagle Small Cap Growth Fund mentioned Halozyme Therapeutics, Inc. (NASDAQ:HALO) and explained its insights for the company. Founded in 1998, Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a San Diego, California-based biotechnology company with a $5.5 billion market capitalization. Halozyme Therapeutics, Inc. (NASDAQ:HALO) delivered a -1.67% return since the beginning of the year, while its 12-month returns are down by -2.97%. The stock closed at $39.54 per share on September 30, 2022.

Here is what Carillon Eagle Small Cap Growth Fund has to say about Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its Q2 2022 investor letter:

“Halozyme Therapeutics is a biopharmaceutical technology platform company. In what was a bit of a flight to quality situation, the stock rose as investors appreciated the company’s ability to generate profits and positive cash flows, as well as the fact it won’t require dilutive equity issuance to fund expansion. These are all characteristics that are often incredibly difficult to come by in the biotechnology space. Halozyme also completed an acquisition in the quarter that adds an additional growth platform to the company’s existing business and that could bring significant synergies over time.”

Photo by National Cancer Institute on Unsplash

Our calculations show that Halozyme Therapeutics, Inc. (NASDAQ:HALO) fell short and didn’t make it on our list of the 30 Most Popular Stocks Among Hedge Funds. Halozyme Therapeutics, Inc. (NASDAQ:HALO) was in 21 hedge fund portfolios at the end of the second quarter of 2022, compared to 21 funds in the previous quarter. Halozyme Therapeutics, Inc. (NASDAQ:HALO) delivered a -11.11% return in the past 3 months.

In May 2022, we also shared another hedge fund’s views on Halozyme Therapeutics, Inc. (NASDAQ:HALO) in another article. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters 2022 Q2 page.

Disclosure: None. This article is originally published at Insider Monkey.